#United States #Washington #Clinical Trials #regenerative medicine #Osteoarthritis Treatment

ROSM Selected for Groundbreaking Osteoarthritis Clinical Trial

Regenerative Orthopedics & Sports Medicine (ROSM) is excited to announce its recent designation as a leading clinical site for an innovative study aimed at revolutionizing the treatment of osteoarthritis (OA). This initiative is made possible through a generous $1 million grant from the Maryland Stem Cell Research Fund (MSCRF). Partnering with BioTech innovators Britecyte and Amarex, ROSM will embark on a Phase 1/2a clinical trial, focusing on an advanced Adipose Tissue Allograft (BRC-OA) therapy. This promising treatment seeks not only to alleviate symptoms but to potentially reverse the progression of knee osteoarthritis, a debilitating condition affecting millions.

A New Era in Pain Management

Dr. John L Ferrell III, MD, who serves as Founder and Director at ROSM, has taken on the dual role of Co-Principal Investigator (Co-PI) for this important study. Under his guidance, ROSM reaffirms its commitment to pioneering minimally invasive regenerative medicine practices. "We established ROSM with the vision of optimizing performance naturally and assisting our patients in resuming their active lifestyles without the need for invasive surgeries," expressed Dr. Ferrell. He emphasizes that this clinical trial represents a leap forward in orthopedics, focusing on biological solutions to heal damaged tissue, rather than just suppressing pain.

Collaboration with Local Innovators

The collaboration between ROSM, Britecyte, and Amarex highlights the robust life sciences community of Maryland. This collective initiative not only combines cutting-edge biotechnology and clinical research capabilities but also exemplifies the spirit of teamwork in addressing a major health concern. With knee OA being one of the leading causes of disability in adults, alternative treatments are critically needed. Presently, patients often face limited options, primarily revolving around pain management or invasive knee replacement surgery.

This trial represents a regenerative alternative aligned with ROSM’s foundational philosophy: enhancing the body's inherent healing capabilities. By shifting the focus to biological treatments, the hope is to provide patients with a functional return to active living instead of merely managing chronic pain and discomfort.

The Path Ahead: Research and Patient Care

Participants in the clinical trial will receive access to cutting-edge treatment protocols, detailing how the innovative BRC-OA therapy works. Instead of operating fundamentally as a pain relief measure, this therapy's core objective is to regenerate and heal knee tissue actively.

The ROSM team is keen to provide insights into the future of osteoarthritis treatments through careful research and tangible results. For anyone looking for information regarding knee osteoarthritis or chronic injuries, resources can be accessed at rosm.org.

About ROSM

Regenerative Orthopedics & Sports Medicine (ROSM) stands out as a progressive organization specializing in updated musculoskeletal and spine care. By leveraging minimally invasive treatments and innovative regenerative medicine approaches, the organization aims to help patients avoid surgical interventions and reclaim their favorite activities. With facilities across Maryland, Washington D.C., and Virginia, ROSM remains dedicated to improving the quality of life for those suffering from chronic musculoskeletal issues.